Arnon Johnathan, Elia Anna, Nevo Yuval, Lossos Alexander, Nechushtan Hovav
Sharett Institute of Oncology, Hadassah University Medical Center, The Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Department of Pathology, Hadassah University Medical Center, The Faculty of Medicine, Hebrew University, Jerusalem, Israel.
JTO Clin Res Rep. 2021 Aug 9;2(9):100217. doi: 10.1016/j.jtocrr.2021.100217. eCollection 2021 Sep.
SCLC is frequently associated with paraneoplastic syndromes, including dermatomyositis. Patients with malignancy-associated dermatomyositis express a specific autoantibody pattern usually positive for anti-transcription intermediary factor 1-γ (TIF1-γ), suggesting anti-TIF1-γ plays a role in development of malignancy-associated dermatomyositis. We present a case of a patient with SCLC, paraneoplastic dermatomyositis, positive anti-TIF1-γ, and a point mutation in TIF1-γ coding gene, with prominent clinical response to chemoradiation. We suggest that this point mutation is pathogenic, providing evidence for the development of paraneoplastic dermatomyositis through immune cross-reactivity.
小细胞肺癌(SCLC)常与副肿瘤综合征相关,包括皮肌炎。恶性肿瘤相关皮肌炎患者表现出特定的自身抗体模式,通常抗转录中介因子1-γ(TIF1-γ)呈阳性,提示抗TIF1-γ在恶性肿瘤相关皮肌炎的发生中起作用。我们报告一例小细胞肺癌、副肿瘤性皮肌炎、抗TIF1-γ阳性且TIF1-γ编码基因存在点突变的患者,该患者对放化疗有显著临床反应。我们认为该点突变具有致病性,为通过免疫交叉反应发生副肿瘤性皮肌炎提供了证据。